Australia-Based Company Begins Sales of Exclusive Human Proteins to Global Research Reagents Market
Apollo Life Sciences is the first and only company in the global reagents market to offer an array of commercialized proteins expressed solely from human cells rather than from rodent or traditional bacteria cells. Proteins from other sources, such as bacteria or insects, have different attachments and behave differently in both experiments and in the human body. Apolloâ€™s proteins are unique because they have human attachments, and thus perform like proteins in the human body. Researchers that use human proteins for their work will now be better able to both simulate human effects and predict the outcomes of clinical trials. The worldwide protein reagents market is estimated at $400 million US per year and includes pharmaceutical companies, university researchers, and hospitals.